Roxithromycin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Roxithromycin: From Bacterial Infections to Leprosy
One-Sentence Summary
Roxithromycin is a 14-membered macrolide antibiotic conventionally used to treat bacterial infections (e.g. respiratory tract and skin/soft-tissue infections); detailed original-indication and mechanism-of-action data were not available in this evidence pack. The TxGNN model predicts it may be effective for Leprosy (Hansen’s disease), supported by 0 clinical trials but 5 preclinical/mechanistic publications demonstrating in vitro and in vivo activity against Mycobacterium leprae. This is early-stage, mechanism-level evidence only — no human clinical data currently exist for this specific indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections (macrolide antibiotic class); specific approved-indication text not available — drug is not currently registered in South Africa |
| Predicted New Indication | Leprosy |
| TxGNN Prediction Score | 99.70% |
| Evidence Level | L4 (preclinical/mechanistic studies only) |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data for roxithromycin is not available in this evidence pack. Based on known pharmacological class information, roxithromycin is a macrolide antibiotic that, like other agents in this class (e.g. clarithromycin, erythromycin), is understood to inhibit bacterial protein synthesis by reversibly binding the 50S ribosomal subunit.
The literature evidence gathered here shows that roxithromycin has demonstrated direct in vitro and in vivo activity against Mycobacterium leprae, the causative organism of leprosy. In a mouse footpad infection model, roxithromycin was found to be bactericidal against M. leprae, though less potent than clarithromycin in the same study. Earlier in vitro work using mouse peritoneal macrophages and ATP/lipid-synthesis assays similarly identified roxithromycin among several macrolides with measurable anti-M. leprae activity. A Japanese leprosy-literature review further notes that roxithromycin, alongside clarithromycin, minocycline and fosfomycin, exhibits combined anti-mycobacterial and anti-inflammatory/immunomodulatory activity — a property considered relevant to managing leprosy-associated peripheral neuropathy.
This gives the prediction reasonable mechanistic plausibility: it is consistent with the established antimycobacterial activity of the macrolide class, and roxithromycin specifically has documented (if modest, relative to clarithromycin) activity against the causative organism. However, all supporting evidence is preclinical (in vitro/animal models) or narrative review — no controlled human studies of roxithromycin in leprosy were identified.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10481449 | 1999 | Review/Clinical commentary | Nihon Hansenbyo Gakkai Zasshi (Japanese Journal of Leprosy) | Roxithromycin, alongside clarithromycin, minocycline and fosfomycin, shows combined anti-M. leprae and anti-inflammatory/immunomodulatory activity, relevant to control of leprous peripheral neuropathy |
| 1648889 | 1991 | Preclinical (animal model) | Antimicrobial Agents and Chemotherapy | In a mouse footpad model, roxithromycin and clarithromycin were consistently active and bactericidal against M. leprae; erythromycin and azithromycin were inactive, and clarithromycin was superior to roxithromycin |
| 2665640 | 1989 | Preclinical (in vitro) | Antimicrobial Agents and Chemotherapy | In vitro screening of ~25 antimicrobials (including roxithromycin) against M. leprae in mouse peritoneal macrophages, using phenolic glycolipid I synthesis inhibition as a marker of activity |
| 3072920 | 1988 | Preclinical (in vitro/in vivo) | Antimicrobial Agents and Chemotherapy | Assessed relative in vitro/in vivo activity of newer macrolides (including roxithromycin) against M. leprae, building on earlier erythromycin activity data |
| 12762831 | 2003 | Review | American Journal of Clinical Dermatology | General review of macrolide use in skin/cutaneous bacterial infections, including mechanism of action (reversible binding to bacterial ribosome) and drug-interaction considerations |
South Africa Market Information
Roxithromycin is not currently registered with SAHPRA and has no marketed products or approved indications on file in this evidence pack.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for the leprosy indication is limited to preclinical in vitro/animal-model studies and narrative reviews (Evidence Level L4) — no human clinical trials exist, and roxithromycin was found to be less potent than clarithromycin in the one head-to-head animal study identified. Combined with the absence of SAHPRA registration and a blocking data gap on approved-label warnings/contraindications, a formal safety review (S1) cannot yet be completed.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (PI): warnings, precautions and contraindications (currently a blocking data gap)
- Detailed mechanism-of-action data from DrugBank (currently a high-severity data gap)
- Head-to-head or dose-ranging human/animal data specifically evaluating roxithromycin (not just clarithromycin) against M. leprae
- A defined regulatory pathway if SAHPRA registration for this indication is to be pursued
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.